Treatment patterns and outcomes among adults admitted to hospital in the U.K. due to plaque or erythrodermic psoriasis

Br J Dermatol. 2017 Sep;177(3):e52-e54. doi: 10.1111/bjd.15270. Epub 2017 Jul 25.

Authors

C Schaefer¹, C Mamolo², J C Cappelleri², S Daniel³, C Le⁴, S Tatulych², C E M Griffiths⁵, P J Hampton⁶

Affiliations

¹ Covance Market Access Services Inc., Gaithersburg, MD, U.S.A.
² Pfizer Inc., Eastern Point Road, Groton, CT, 06340, U.S.A.
³ Covance Market Access Services Inc., Conshohocken, PA, U.S.A.
⁴ Covance Market Access Services Inc., San Diego, CA, U.S.A.
⁵ Dermatology Centre, Salford Royal Hospital, University of Manchester, Manchester Academic Health Science Centre, Manchester, U.K.
⁶ Newcastle Hospitals NHS Trust, Newcastle, U.K.

PMID: 28012158
DOI: 10.1111/bjd.15270

No abstract available

Publication types

Evaluation Study
Letter
Multicenter Study

MeSH terms

Adult
Biological Products / therapeutic use
Dermatitis, Exfoliative / therapy*
Dermatologic Agents / therapeutic use
Employment / statistics & numerical data
Female
Hospitalization / statistics & numerical data
Humans
Male
Middle Aged
Patient Reported Outcome Measures
Phototherapy / statistics & numerical data
Psoriasis / therapy*
Treatment Outcome
United Kingdom

Substances

Biological Products
Dermatologic Agents